Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial (vol 19, pg 1530, 2018)

Trotman J.; Barrington S. F.; Belada D.

首页> 外文期刊>The lancet oncology >Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial (vol 19, pg 1530, 2018)

【24h】

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial (vol 19, pg 1530, 2018)

机译：卵泡淋巴瘤第一线免疫化疗法后诱导宠物反应的预后价值（镓）：随机，第3阶段试验的二次分析（Vol 19，PG 1530,2018）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The lancet oncology》 |2019年第6期|共1页
作者
Trotman J.; Barrington S. F.; Belada D.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献

1. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial (vol 19, pg 1530, 2018) [J] . Trotman J., Barrington S. F., Belada D. The lancet oncology . 2019,第6期

机译：卵泡淋巴瘤第一线免疫化疗法后诱导宠物反应的预后价值（镓）：随机，第3阶段试验的二次分析（Vol 19，PG 1530,2018）
2. Baseline PET-Derived Metabolic Tumor Volume Metrics Did Not Predict Outcomes in Follicular Lymphoma Patients Treated with First-Line Immunochemotherapy and Antibody Maintenance in the Phase III GALLIUM Study [J] . Barrington Sally F., Trotman Judith, Sahin Deniz, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：基线宠物衍生的代谢肿瘤体积度量并未预测在第III期镓研究中用一线免疫化治疗和抗体维持治疗的滤泡淋巴瘤患者的结果
3. Bone Marrow Biopsy Impacts Response Assessment in a Minority of Patients with Follicular Lymphoma and Diffuse Large B Cell Lymphoma Treated with Immunochemotherapy: Results from the Randomized Phase III GALLIUM and GOYA Trials [J] . Rutherford Sarah C., Herold Michael, Hiddemann Wolfgang, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：骨髓活检影响少数卵泡淋巴瘤患者的响应评估，并用免疫化治疗治疗的弥漫性大B细胞淋巴瘤：随机期III镓和戈亚试验的结果
4. Response‐adapted treatment with rituximab bendamustine mitoxantrone and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial [O] . Francisco‐Javier Peñalver, José‐Antonio Márquez, Soledad Durán, 2019

机译：一线免疫化疗后复发或难治性滤泡性淋巴瘤患者应用利妥昔单抗苯达莫司汀米托蒽醌和地塞米松进行适应性治疗然后进行利妥昔单抗维持：RBMDGELTAMO08 II期试验的结果
5. PROGNOSTIC VALUE OF PET-CT AFTER FIRST-LINE IMMUNOCHEMOTHERAPY FOR FOLLICULAR LYMPHOMA IN THE PHASE III GALLIUM STUDY [O] . J. Trotman, S. Barrington, D. Belada, 2017

机译：PET-CT的预后价值在第三阶段滤泡淋巴瘤中的一线免疫化学疗法

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial (vol 19, pg 1530, 2018)

著录项

相似文献

相关主题

期刊订阅